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Wilson disease is an autosomal recessive disorder of copper metabolism. Diagnosis depends primarily on clinical
features, biochemical parameters and the presence of the Kayser-Fleischer ring. Genetic analysis for mutations
within ATP7B is a convincing diagnostic tool. The traditional treatment for WD includes chelation of excessive
copper accumulation and reduction of copper intake. Medical therapy is effective but WD is not yet curable. Liver
transplantation is especially helpful for patients who fail to respond to medical therapy or present with fulminant
liver failure, although evaluation of its long-term effect are still in need.
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Wilson disease (WD) is an autosomal recessive disorder,
in which defective biliary excretion of copper results in
its accumulation in liver, brain, kidney and cornea. The
WD gene, ATP7B, is located on chromosome 13q14.3. It
encodes a P-type ATPase, ATP7B. The incidence of WD
is estimated to be 1 in 30,000 individuals, and the gene
frequency is about 1 in 90 among many ethnic groups
[1]. Diagnosis solely based on clinical manifestations and
biochemical parameters lacks accuracy. Thus, a new
diagnostic scoring system has been proposed [2], which
includes the mutation analysis. Today, symptoms of WD
can be effectively controlled with medical therapy and
liver transplantation but it is still deemed incurable. Fu-
ture efforts will likely involve gene therapy and other
novel interventions. In this review, we will firstly review
the pathogenesis of WD and secondly, discuss the
advances in the treatment of WD.
Pathogenesis
Copper is an essential trace element in the human body
and a required component of many proteins. Excess cop-
per causes oxidative damage to hepatocytes and allows
spillage of free copper into the blood. It will overload* Correspondence: zhiyingwu@fudan.edu.cn
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reproduction in any medium, provided the orother organs such as the brain, kidney and cornea, initi-
ating toxic damage [1]. However, excessive cellular cop-
per damages neuronal and metabolic functions [3],
which is displayed by the wide spectrum of symptoms in
WD. The defective gene, ATP7B, is responsible for this
disorder. Despite intensive studies over the past decade,
the mechanisms of how the defective ATP7B disrupts
the copper excretion and regulations of ATP7B remain a
myth.Copper homeostasis
The body’s essential copper requirement is about 1–2 mg
per day. Dietary intake alone suffices the daily need. Cop-
per is absorbed by the intestinal cells and stored with
metallothionein in a non-toxic form. It is later delivered
into the circulation by a copper transporter protein,
ATP7A on the membrane of enterocytes [4]. The copper
is then transported to the liver tagged with albumin,
where it is uptaken by hepatocytes. Within these cells,
the ATOX1 chaperone protein directs copper to its bind-
ing targets [5]. Some are bound to metallothionein, an
intracellular chelator of harmful or excessive metal, for
storage, and the rest is excreted into biliary canaliculi
under the regulation of ATP7B.
The WD gene, ATP7B, encodes a putative copper-
transporting P-type ATPase, ATP7B. ATP7B assumes
double roles. It participates in the biliary excretion
of copper and incorporates copper into nascental Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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organization (including 8 domains), an ATP-binding
domain toward the carboxy terminus, and an amino
tail comprised of 6 copper-binding units. It normally
locates in the trans-Golgi network (TGN). ATP7B traf-
ficking is regulated with its copper-translocation cycle,
with cytosolic vesicular localization associated with the
acyl-phosphate intermediate. Copper-chelation studies
with some mutants clearly demonstrated a require-
ment for copper in ATP7B trafficking, suggesting the
presence of an additional copper-binding site(s) within
the protein [8].
Copper transportation capacity of ATP7B mutants is
reduced or completely lost. One study using transient
transfection and triple-label immunofluorescence mi-
croscopy shows that WD associated protein variation
have different intracellular localizations compared with
wild-type ATP7B protein [9]. This is later confirmed by
Huster et al. in Sf9 cells. In addition, Huster et al. [10]
points out that if the mutation causes ATP7B misfold-
ing, it results in severe dysfunctions. Misfolded protein
cannot exit from the ER, thus abolishing copper delivery.
In addition, misfolding of ATP7B is correctable in vitro
by pharmacological chaperones 4-phenylbutyrate and
curcumin, though its application in vivo requires further
elucidation [11].
ATP7B function is also impaired if the mutant has a
dysfunctional ATP-binding domain. Using yeast as a
model system, Hsi et al. [8] discovered that sequence
variations in the ATP-binding domain of ATP7B affect
copper transport. Not coincidentally, Huster et al. also
discovered that ATP7B mutants would lose its copper
delivery capacity with intact copper binding capacity if
the mutations happen in ATP binding-domain or
spatially-adjacent region [10].
Copper toxicity
ATP7B dysfunction results in hepatic copper accumula-
tion and subsequent overflow of copper to other organs
like brain, kidney and cornea. Copper toxicity and mito-
chondrial dysfunction is closely related. The energy pro-
duction of mitochondria is disrupted. In ATP7B
knockout (ATP7B−/−) rats, Zischka et al. reports that
liver mitochondria contain enlarged cristae, widened
intermembrane spaces and a large amount of copper ac-
cumulation [12]. Detectable abnormalities, including
impaired oxidative phosphorylation and biochemical
signs of oxidative damage, come later. Respiratory chain
complex I activity is increased in livers and brains of
ATP7B−/− mice, whereas complex II, III and IV activities
are reduced [13]. Mitochondria have respiratory chain
complex I as their major source of reactive oxygen stress
production [14].Besides, sterol metabolism is also severely disrupted
[13]. Cardiolipin is an important component of mito-
chondrial inner membrane. The free-radical fragmenta-
tion of cardiolipin, phosphatidic acid (PA) and
phosphatidylhydroxyacetone (PHA) are more abundant
in the liver of ATP7B−/− mice over 32 weeks old com-
pared with control group at the same age [15]. It’s still
not clear whether the copper-accumulation-induced oxi-
dative stress leads to dysfunction of mitochondria or the
copper accumulation in mitochondria leads to the pro-
duction of oxidative stress. It’s probable that both
mechanisms are equally important.
As a result of ROS injury and mitochondria dysfunc-
tion, apoptosis finally occurs. It is still unclear which
pathways of apoptosis are responsible for cell loss in
organ lesions of WD patients. Strand S et al. [16] discov-
ered that copper (II) was an inducer of CD95 mediated
apoptosis in livers of WD patients with fulminant liver
failure. Addition of antioxidant and radical scavengers
could inhibit apoptosis induced by copper [17]. The
neuron degeneration is more complicated that apoptosis
in the liver. Despite the detection of mitochondria
autophagy, ROS injury alone can’t explain why dopamin-
ergic neurons are more vulnerable to copper toxicity.
Paris I et al. [18] pointed out that copper would form a
complex with dopamine. In vitro, treatment with
copper-dopamine complex would cause apoptosis of
RCSN-3 cells (a cell line that expresses dopamine, nor-
epinephrine and serotonin transporters). During the
process, mitochondrial autophagy and oligonucleosomal
DNA fragmentation occurred. The apoptosis is inde-
pendent of caspase 3 pathway.
Regulations of ATP7B
Some factors are believed to modulate the function of
ATP7B, including Copper metabolism (Murr1) domain-
containing protein 1 (COMMD1), clusterin, X-linked in-
hibitor of apoptosis (XIAP) and solute carrier family 33
(acetyl-CoA transporter) member 1 (SLC33A1).
COMMD1 is a protein responsible for canine copper
metabolism disorder [19]. It facilitates the degradation of
ATP7B. It specifically interacts with the amino-terminus
of ATP7B. This interaction is independent of intracellu-
lar copper levels and copper chaperone antioxidant pro-
tein 1 (ATOX1) expression [20]. It is noticed that more
COMMD1 binds to unstable, misfolded ATP7B [21].
Over-expression of COMMD1 decreases the amount of
ATP7B expression whereas knockdown of COMMD1
increases it [21]. So far, sequencing analysis reports no
evidence to implicate the COMMD1 protein in copper-
storage disorders of undefined etiology in human beings
[22].
Clusterin is recognized as an extracellular chaperone.
It also facilitates ATP7B degradation. Its role closely
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Clusterin knockdown and over-expression increases and
decreases the levels of COMMD1 respectively. However,
their mechanisms of regulating ATP7B levels are inde-
pendent of each other. Whereas COMMD1 are sensitive
to misfolded ATP7B, clusterin respond to oxidative
stress [21].
X-linked inhibitor of apoptosis (XIAP), an anti-
apoptotic protein, has recently been shown to regulate
copper homeostasis. XIAP levels are greatly reduced in
cells cultured under high copper conditions [23]. XIAP
exerts its role in two different ways [24]: First, XIAP,
when bounded with copper, will lead to its conform-
ational changes, which results in increased susceptibility
to apoptotic stimuli; second, XIAP promotes the degrad-
ation of COMMD1 by protoeasome. A novel mutation
of its copper chaperone copper chaperone for super-
oxide dismutase (CCS) has been reported in a patient
[25]. Although this CCS mutant doesn’t show impaired
interaction with XIAP, further research is needed to de-
termine whether CCS mutation is able to affect
COMMD1 level by altering copper delivery to XIAP.
Clinical management
Diet
One way to reduce copper absorption is to control the
copper content of food. Patients should avoid having
foods that contain high concentration of copper, such as
chocolate, liver, nuts, mushrooms, and shellfish, and
using the copper apparatus for food. Wu et al. have
found low-copper diet and zinc are effective treatment
for the presymptomatic WD patients [26].
Medical therapy
Traditional treatment of WD focuses on promotion of cop-
per excretion and reduction of copper intake. Initial treat-
ment for symptomatic patients with WD should include a
chelating agent, D-penicillamine or trientine (bettered toler-
ated than D-penicillamine). Zinc is recommended by some
experts as a first line therapy in neurological patients [27].
Maintenance therapy of presymptomatic patients or those
with neurological symptoms usually requires a chelating
agent or zinc [27]. Ammonium tetrathiomolybdate shows
optimal effect in treating patients presented with neuro-
logical symptoms, though not yet commercially available
[28,29]. The efficacy of copper excretion is measured by the
levels of urinary copper.D-penicillamine D-penicillamine chelates copper inside
the body. It mobilizes intracellular copper into the
circulation and enhances urinary excretion of copper.
McArdle et al. [30] found that D-penicillamine increases
metallothionein mRNA levels without changing eitherthe rate of copper uptake or the amount of copper
within mouse hepatocytes. Metallothionein chelates the
excessive copper to form a non-toxic combination [31].
On the contrary, Xu et al. [32] discovers that in Long-
Evans Cinnamon (LEC) rats, an animal model of WD,
excessive copper accumulation induces metallothionein
in hepatocytes whereas D-penicillamine reduces the level
of both metallothionein-l mRNA and metallothionein
protein.
The initial dose of penicillamine is 750–1500 mg per
day in two to four divided doses for adults. Dosing in
children is 20 mg/kg/day to the nearest 250 mg, divided
in two or three divided doses [27]. The treatment is best
taken 1 hour before or 2 hours after food. Absorption is
estimated to be only 50% if it is taken with a meal. The
use of lower initial doses, 125–250 mg per day, increas-
ing over a few weeks, can enhance tolerance to the
agent. Pyridoxine (vitamin B6) is added routinely to the
treatment regimen in a dosage of 20–50 mg daily, as its
deficiency is associated with neurological worsening
induced by D-penicillamine [33], which is irreversible in
some cases.
The use of D-penicillamine remains controversial for
decades due to its adverse effects. Someone suggests that
D-penicillamine should not be used as initial therapy in
WD [34,35]. Apart from neurological worsening, they in-
clude early reactions such as fever, rash, lymphadenop-
athy or late reactions such as bone marrow and renal
toxicity [36]. Newly reported unfavorable effects consist
of ANCA-vasculitis in WD [37] and dermatology tox-
icity, such as progeric changes in the skin, such as pem-
phigous or pemphigoid lesions [38]. Severe adverse
effects necessitate discontinuation of D-penicillamine
and change of regimen in 20-30% of patients [39,40].
The reasons for the neurological deterioration of the
D-penicillamine are still unknown. Depletion of pyridox-
ine may be one of them [33]. Radical therapies that dras-
tically lower serum copper level are found to induce
partial status epilepticus as well as severe deterioration
of neurological symptoms in one patient, whose condi-
tions improved shortly after discontinuing D-
penicillamine and having a high copper diet [41].
Increased free copper concentrations are found in the
serum and brain, and declined protein-bound copper
concentrations are found in the brain of toxic milk mice
during D-penicillamine administration [42]. Immuno-
flurescence staining shows intense staining of ATP7A in
the choroid plexus but rare ATP7A and copper trans-
porter 1 (CTR1) on the blood–brain-barrier, which sug-
gests that D-penicillamine mobilizes free copper from
the brain parenchyma rather than from the blood.
During administration of D-penicillamine, periodic
clinical, hematological, biochemical and routine urinary
parameters are monitored weekly for 1 month, then
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after. It’s notable that cessation of penicillamine without
replacement treatment causes rapid progression to fatal
fulminant hepatitis [43].Trientine Trientine has a polyamine structure, which
chelates copper by the formation of stable complexes
with the four constituent nitrogens in a planar ring. It is
debatable whether the two agents mobilize different
pools of copper. The initial dose is 900–2700 mg per
day in two to three divided doses. Maintenance therapy
is 900–1500 mg per day. As in the case of penicillamine,
trientine should be given orally 1 hour before or 2 hours
after food [27].
Trientine is a less potent copper remover than D-
penicillamine with its toxic profile similar to that of D-
penicillamine, although side effects are less frequent and
generally milder [44]. It is believed that neurological
deteriorations are less frequent in trientine than in D-
penicillamine [45]. However, Weiss et al. [46,47]
reported a less frequent neurological deterioration in
patients treated with D-penicillamine than with trientine
while the extent of improvement was similar. Weiss
et al. [47] reported that neurological deteriorations hap-
pened to patients in all treatment regimen including
D-penicillamine, trientine, zinc and combination ther-
apy, and the P values were not significant.
Evidence grows for the effectiveness of trientine. Askari
et al. [48] studied 9 adults with severe liver disease identi-
fied over a 10 year period. They received initial treatment
with trientine (1000 mg/day) and zinc (150 mg/day).
Only one patient had hepatic encephalopathy. One pa-
tient developed mild neurological symptoms so the pa-
tient was given ammonium tetrathiomolybdate and zinc
after 2 weeks of the original treatment. In the eight
patients receiving trientine and zinc, the combination
was given for at least 4 months and then maintenance
zinc treatment was used. Over the first 12 months of
treatment, prothrombin time and raised bilirubin and al-
bumin concentrations returned to normal, and ascites
disappeared. Benefit was maintained over 12 months to
14 years of follow-up. Taylor et al. [40] provides evidence
that trientine is as efficacious as penicillamine with a
lower side effect profile in pediatric patients. However,
trientine is not yet commercially available in China.Zinc Zinc induces intestinal metallothionein, which pre-
ferentially binds to copper within the duodenal entero-
cytes. Thus, copper absorption into the circulation is
reduced, and copper is lost when the enterocytes are
shed during normal cell turnover. Continuing copper
losses in combination with reduced absorption lead to a
negative copper balance. Furthermore zinc can inducecopper-binding metallothionein in hepatocytes, thereby
reducing the damaging effects of free copper.
Zinc has been used successfully in asymptomatic or
presymptomatic patients. Wu et al. [26] have identified
17 presymptomatic patients with WD by genetic analysis
and prophylactic treatment of 14 patients with zinc over
3 to 5 years resulted in lowered level of urinary copper.
None of the patients developed clinical symptoms of
WD or adverse effects of zinc therapy by the end of the
study period. In contrast, 3 patients who refused treat-
ment had symptomatic progression. Brewer et al. [49]
conclude that zinc is effective as a sole therapy and that
it has low toxicity based on data from the long-term fol-
low-up of maintenance zinc treatment of 141 symptom-
atic and presymptomatic patients with WD. It’s the same
for children and pregnant women, although more data
should be acquired. In patients with severe hepatic dis-
ease, maintenance therapy with zinc was effective after
an initial period of treatment with trientine and zinc
[48].
When the patients are given zinc monotherapy, liver
functions should be regularly monitored. Among
patients with hepatic manifestations, non-response to
zinc monotherapy is not uncommon. This is not due to
noncompliance. If the level of AST, ALT and γ-GT
remains in a high level after the initiation of the zinc
therapy, it often suggests a poor response and a change
in therapy should be considered as soon as possible [50].
Patients discontinue zinc therapy mostly due to
gastrointestinal discomfort. It is more common with zinc
sulfate than zinc acetate. During a long-term follow-up
by Bruha et al., with a median follow-up of 12 years, no
adverse events were reported with zinc acetate [50].
Ammonium tetrathiomolybdate Tetrathiomolybdate
has a unique mechanism of action. Its four sulfur groups
allow it to form a stable tripartite complex with copper
and protein [51,52]. Ammonium tetrathiomolybdate is
well-absorbed with or without food. It forms a complex
with copper in the food. When it is given away from
food, it forms a complex with available copper and albu-
min so that it can’t be up-taken or utilized for intracellu-
lar process [29].
Although not yet commercially available, its high effi-
cacy and rare neurological deterioration compared with
trientine makes it a potential cure for WD patients with
neurological symptoms [53]. One out of 25 (4%) patients
treated with tetrathiomolybdate while 6 of 23 (26%)
patients treated with trientine showed neurological de-
terioration during an 8-week study [45]. Unlike trientine,
tetrathiomolybdate stably lowers the serum “free copper”
level, which may explain uncommon neurological deteri-
oration. Its recommended dose is 120 mg daily as 20 mg
with meals and 20 mg between meals for 2 weeks, and
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10 mg 3 times daily between meals [53].
Symptomatic treatment Despite the generally well re-
sponse to chelation therapy with zinc, additional treat-
ments to control the disturbing symptoms are still
necessary for some patients. Neurological symptoms are
usually more refractory than hepatic damages. Neuro-
logical symptoms can be categorized into parkinsonism,
dysarthria, dystonia, tremor, pseudosclerosis [54]. Par-
kinsonism can be treated with L-dopa, dopamine ago-
nists [54] and anticholinergics(trihexyphenidyl) [55].
Essential tremor-like tremor is treated with beta-blocker
(propranolol) or barbituate (primidone) [55]. Dystonia
can be treated with trihexyphenidyl, baclofen, valium or
dopamine antagonist (tiapride) and botulinem injection
[56,57]. Proxysmal dystonic movement can be treated
with oxcarbazepine [56]. Gabapentine can be used when
dealing with penicillamine-induced dystonia when other
options fail [58]. However, there are only a small number
of case reports regarding symptomatic treatments and
the conclusions are inconsistent.
Experience from China In China, most Departments of
Neurology treat WD patients according to WD guide-
line. A few neurologists choose traditional Chinese
medicine (TCM) and decoppering agents other than D-
penicillamine and trientine. Besides, aggressive decop-
pering therapies involving intravenous 2, 3-dimercapto-
propane-1-sulfonate (DMPS) will also be applied.
Unfortunately, there are only a limited number of
reports regarding this aspect. Aggressive decoppering
therapies are theoretically dangerous for patients be-
cause rapid mobilization and depletion of deposited cop-
per are associated with neurological worsening.
However, according to the aggressive therapy reported
by Yang et al. [59], 84.85% of the patients showed im-
provement and 11.11% of the patients were symptom
free based on Goldstein activity of daily life scale. How-
ever, the account of adverse events was not given.
TCM is mostly used in combination with decoppering
agents. The most commonly used TCM agents include
Gandou Decoction, Gandou Tablets, and oxymatrine.
The choice of TCM agents is empirical and lacking con-
sensus among neurologists. So far, there is no strong evi-
dence to recommend TCM in treating WD due to the
methodical limitations of these clinical researches. Most
researches did not provide information on how the ran-
dom allocation was generated and concealed. Based on a
systematic review of 9 randomized controlled trials [60],
TCM therapy are generally associated with better re-
sponse and fewer adverse events. However, 8 out of the
9 randomized control trials mentioned above lacked
blinding methods and none of them reported dropout.As a result, the optimistic outcomes of TCM therapy are
questionable.Liver transplantation
There are some reports of successful management of
acute liver disease by medical therapy [61]. However, if
medical therapy fails to suppress the progression of the
disease, orthotopic liver transplantation (OLT) is the
only alternative treatment. It is indicated for WD
patients with acute liver failure when the revised King’s
score is 11 or higher and patients with decompensated
cirrhosis that’s unresponsive to chelation therapy [27].
Liver transplantations of these individuals can be
achieved by a cadaveric donor or living donor transplant,
even if the donor is a heterozygous carrier [27].
OLT generally gives excellent results. The one year
survival rate and 5 year survival rate in pediatric patients
are 90.1% and 89% in comparison with a survival of
88.3% and 86% for adults in a multi-center observational
study over 20 years [62]. The OLT also corrects the
underlying renal disorder [63]. However, survival is only
one aspect of patients’ well-being. Neurological compli-
cations can be quite common. The immunosuppressive
agents would leave the patients vulnerable to infections.
Lack of compliance in the immunosuppressive agents
would lead to acute hepatic failure [64]. Long-term fol-
low-up would be in need to assess the efficacy of OLT.
Liver transplantation is not recommended for patients
with neurological and psychiatric symptoms [65]. How-
ever, some patients choose to undergo transplantation
for their neurological impairment and some patients
with liver damage show neurological improvement after
the surgery [66-70]. Otherwise, there are risks associated
with the procedure of liver transplantation and the fol-
lowing immunosuppressive therapy [71,72]. According
to Enrol et al. [73], 10/17 of the pediatric patients who
were free from neurological symptoms before the opera-
tions have as many as 16 episodes afterwards. The au-
thor largely attributes these complications to the use of
immunosuppressive agent tacrolimus and cyclosporine
instead of a manifestation of latent neurological symp-
toms. The serum chemistry panel suggested that those
patients didn’t have metabolic disorders although hep-
atic encephalopathy prior to the surgery was a possible
risk factor for post-operational neurological complica-
tions. MRI also revealed posterior leukoencephalopathy
syndrome in 2 patients with seizure but EEG didn’t
reveal any epileptiform abnormalities. These complica-
tions tended to be short-lived and resolved promptly
after discontinuing or reducing the dose of immunosup-
pressive agents [73]. Other observations show, although
the mild neurological symptoms may improve after OLT,
concomitant severe or moderate neurological and
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prognostic factors for post-OLT survival [74].
There are few absolute contraindications for liver
transplantation. Patients with poor cardiac and pulmon-
ary functions, namely patients with severe hypoxia or
right arterial pressure greater than 60 mm Hg rarely sur-
vive surgery and the perioperative recovery period. Be-
fore transplantation is attempted, patients with
extrahepatic malignancies other than squamous cell skin
carcinoma should be postponed for at least 2 years after
the curative therapy is completed. Significant psychiatric
or neurological disorders and ongoing destructive behav-
ior caused by substance abuse must be under effective
medical control to make sure that the patient can be
compliant after transplantation. Absence of a viable
splanchnic venous inflow system is the most common
surgical contraindication to liver transplantation. If the
entire portal venous system is occluded, the transplant-
ation is rarely successful. Plus, uncontrolled systemic in-
fection is apparently an contraindication to high-dose
immunosuppressive therapy [65,75].
Are the decoppering treatment and the low copper
diet necessary after the transplant? There is no report
yet. Long-term results of liver transplantation are still in
lack of large cohort studies. The development of better
prognostication for neurological progression or improve-
ment of WD by MRI findings or other clinical or bio-
chemical variables will help improve our abilities to
make treatment choices.
Pregnancy
Female WD patients can become pregnant if her copper
status optimized prior to pregnancy. Although there is
some concern over the teratogenicity of D-penicillamine,
withdrawing treatment is more risky than continuing it.
Among 161 reported cases of pregnancies in 83 women
with WD (one of them had successful in vitro fertilization)
treated with D-penicillamine during pregnancy showed
122 births with 119 normal newborns [27].
Low risk of teratogenicity is also true for treatment with
trientine [76] or zinc [77]. Breast feeding under chelation
therapy is not recommended, although there are reports
that children breast fed by mothers on D-penicillamine
show no abnormalities [78]. It is recommended to lower
D-penicillamine during the first trimester and put patients
on the lowered dosage for all trimesters with continued
monitoring. Others recommend administering chelators at
a minimal dose, i.e. 300–600 mg/day in the last trimester to
avoid insufficient copper supply to the fetus or insufficient
wound healing after Cesarean section or episiotomy [79].
The future
Patients faced with a lifelong need for medication and
physicians faced with the results of non-adherence totherapy are the two main arguments. Genetic therapy
and hepatocyte transplantation represent future curative
treatments for WD, along with currently available liver
transplantation. Therapeutic replacement of organs with
healthy cells requires disease-specific strategies. As cop-
per toxicosis due to ATP7B deficiency in WD produces
significant liver injury, disease-specific study of trans-
planted cell proliferation will offer insights into cell and
gene therapy mechanisms. Studies on animal model have
showed that cell therapy will correct genetic disorders
characterized by organ damage, but suitable mechanisms
for inducing transplanted cell proliferation will be crit-
ical for therapeutic success [80]. However, both cell and
liver transplants need immunosuppression to maintain
grafted cells. Future use of stem-cells, ex-vivo modifica-
tion of cells by gene therapy, or better means of indu-
cing immune tolerance may obviate the difficulty of
immunosuppresion and provide a cure for WD by cell
transplantation.
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